AMANDA DAVIS: Open Payments
NPI 1710637459 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 30 payments from 12 companies in 2025. Trend: 2023 $189 · 2024 $649 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 4 | $146 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Corium, LLC | 6 | $89 |
| Neurocrine BioSciences, Inc. | 3 | $81 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Alkermes, Inc. | 2 | $53 |
| ABBVIE INC. | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
Products named: Qelbree, Azstarys, INGREZZA, Auvelity, ARISTADA, REXULTI, VRAYLAR, SPRAVATO.
Industry payments across AL — which companies pay providers there.
